About: ACEI/ARB Use and Risk of Infection or Severity or Mortality of COVID-19: A Systematic Review and Meta-analysis

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: ACEI/ARB Use and Risk of Infection or Severity or Mortality of COVID-19: A Systematic Review and Meta-analysis Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
title	ACEI/ARB Use and Risk of Infection or Severity or Mortality of COVID-19: A Systematic Review and Meta-analysis
Creator	Zhang, Xue Yu, Jiong Jiang, Hai-Yin Pan, Li-Ya
source	Elsevier; Medline; PMC
abstract	We have sparse knowledge of the effects of angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs) on the risk of COVID-19 infection and the progression of this disease. We systematically assessed these relationships. Unrestricted searches of the PubMed, Embase, and Cochrane Library databases were conducted, with an end date of May 9, 2020, to identify relevant studies that met predetermined inclusion criteria. Random-effects models were adopted to estimate the overall relative risk. Fourteen articles involving more than 19000 COVID-19 cases were included. Our results showed that ACEI/ARB exposure is not associated with a higher risk of COVID-19 infection (OR = 0.99; 95% CI, 0.95-1.04; P = 0.672). Among those with COVID-19 infection, ACEI/ARB exposure is not associated with a higher risk of severity (OR = 0.98; 95%CI 0.87-1.09; P = 0.69) or mortality (OR = 0.73, 95%CI 0.5-1.07; P = 0.111). However, ACEI/ARB exposure was associated with a lower risk of mortality compared those with non-ACEI/ARB antihypertensive drugs (OR = 0.48, 95% CI 0.29-0.81; P = 0.006). In conclusion, current evidence did not confirm previous concern regarding a harmful role of ACEI/ARB in COVID-19 patients. The present study support current professional society guidelines to not discontinue ACEIs or ARBs in the setting of the COVID-19 pandemic or COVID-19 patients.
has issue date	2020-05-15(xsd:dateTime)
bibo:doi	10.1016/j.phrs.2020.104927
bibo:pmid	32422341
has license	no-cc
sha1sum (hex)	07a99f9ecccaebe08e95b596e1fb0507c351d0fd
schema:url	https://doi.org/10.1016/j.phrs.2020.104927
resource representing a document's title	ACEI/ARB Use and Risk of Infection or Severity or Mortality of COVID-19: A Systematic Review and Meta-analysis
has PubMed Central identifier	PMC7227582
has PubMed identifier	32422341
schema:publication	Pharmacol Res
resource representing a document's body	covid:07a99f9ecccaebe08e95b596e1fb0507c351d0fd#body_text
is schema:about of	named entity 'infection' named entity 'ARB' named entity 'Journal' named entity 'Meta-analysis' named entity 'Review' named entity 'Use' named entity 'RELATIONSHIPS' named entity 'RISK OF' named entity 'risk' named entity 'COVID-19' named entity 'Review' named entity 'angiotensin receptor blockers' named entity 'angiotensin-converting enzyme inhibitors' named entity 'infection' named entity 'ARBs' named entity 'Risk of Infection' named entity 'Systematic Review' named entity 'respiratory epithelium' named entity 'COVID' named entity 'ACE2' named entity 'ACEI' named entity 'RAS' named entity 'infection' named entity 'infection' named entity 'infectivity' named entity 'systematic review' named entity 'ACEI' named entity 'ACEI' named entity 'clinical outcomes' named entity 'COVID-19.' named entity 'fixed effects model' named entity 'publication bias' named entity 'COVID' named entity 'Statistical significance' named entity 'antihypertensive' named entity 'ACEI' named entity 'ACEI' named entity 'infection' named entity 'sample size' named entity 'ACEI' named entity 'hypertension' named entity 'COVID' named entity 'Embase' named entity 'COVID' named entity 'ACE2' named entity 'COVID' named entity 'COVID' named entity 'COVID' named entity 'comorbidities' named entity 'cohort studies' named entity 'ACEI' named entity 'clinical outcomes' named entity 'extracellular domain' named entity 'study design' named entity 'study design' named entity 'ACEI' named entity 'general population' named entity 'Statistical heterogeneity' named entity 'meta-analysis' named entity 'Q-statistic' named entity 'systematic review' named entity 'confounders' named entity 'heterogeneity' named entity 'acute lung injury' named entity 'hypertension' named entity 'ACEI' named entity 'animal studies' named entity 'Zhejiang Province' named entity 'ACEI' named entity 'ACEI' named entity 'ACE2' named entity 'SARS-CoV-2' named entity 'ACEI' named entity 'ACEI' named entity 'RAS' named entity 'beta blockers' named entity 'ACEI' named entity 'SARS-CoV'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software